Systematic reviews have grown substantially in number across the clinical literature and are now a primary reference point for health professionals and academics alike. Bodies such as the GRADE network have placed these reviews at the centre of guideline development, making the quality of their reporting a matter of considerable practical consequence.
A New Checklist for Paediatric Evidence Synthesis
Against that backdrop, a research team led by Offringa and colleagues has developed an extension to the widely used PRISMA guideline, tailored specifically to systematic reviews of interventions in children and adolescents. The new tool, designated PRISMA-C (PRISMA-Children and Adolescents), was examined in a recent BMJ commentary that explored both its potential value and the broader limitations of reporting checklists in paediatric research.
PRISMA-C sits alongside parallel extensions to two related methodological frameworks — CONSORT, which governs the reporting of clinical trials, and SPIRIT, which covers trial protocols — both published in the same period. Together, these tools represent a coordinated effort to bring greater rigour and consistency to research involving younger populations.
Why Paediatric Research Requires Distinct Guidance
A central premise of PRISMA-C is that children and adolescents are not simply smaller adults. The checklist explicitly recognises contextual considerations that are distinctive to paediatric care, acknowledging that populations below a certain age carry characteristics that bear directly on how systematic review findings should be reported and interpreted.
These distinctions can affect everything from how outcomes are defined and measured to how findings are generalised across different age bands. Standard reporting frameworks developed primarily with adult populations in mind may not adequately capture such nuances, which is the gap PRISMA-C is designed to address.
The Broader Debate on Checklist Utility
The BMJ commentary does not treat PRISMA-C as an uncomplicated advance. It situates the checklist within a wider discussion about the limits of reporting tools in general — a debate that has gained traction as the volume of systematic reviews has increased and concerns about their variable quality have mounted.
Checklists can standardise the presentation of research and make it easier for readers to assess completeness, but they do not in themselves guarantee methodological soundness. The commentary reflects on this tension, suggesting that the value of any reporting extension depends substantially on how it is implemented and whether it is accompanied by genuine improvements in underlying research practice.
Whether PRISMA-C will meaningfully shift the quality of paediatric systematic reviews remains, according to the BMJ piece, an open question — one that will likely be answered only as the checklist is adopted and its effects observed over time.